Blue Sphere Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLSP research report →
Companywww.bluespherecorporate.com
Blue Sphere Corporation operates as a developer and independent power producer in the clean energy production and waste to energy markets. The company focuses on projects related to the acquisition, construction, and development of biogas facilities in the United States, Italy, the Netherlands, the United Kingdom, and Israel. It also focuses on soil amendments, compost, and other by-products.
- CEO
- Shlomo Palas
- IPO
- 2010
- Employees
- 11
- HQ
- Charlotte, NV, US
Price Chart
Valuation
- Market Cap
- $63.70K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- 4.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 16.71%
- Op Margin
- -12.65%
- Net Margin
- -95.80%
- ROE
- 196.08%
- ROIC
- -4.80%
Growth & Income
- Revenue
- $10.90M · 185.14%
- Net Income
- $-10,443,000 · -167.22%
- EPS
- $-0.20 · 80.39%
- Op Income
- $-1,379,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -11.77
- Avg Volume
- 5.83M
Get TickerSpark's AI analysis on BLSP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 18 | Keret Yosef | other | 0 |
| Mar 23, 18 | Daniel Ran | other | 10,000 |
| Mar 7, 18 | Bentovim Lyron L | other | 7,184 |
| Oct 17, 17 | Bentovim Lyron L | other | 5,708 |
| Sep 1, 17 | Ibex Israel Fund 1 LLLP | other | 324,754 |
| Sep 1, 17 | Ibex Israel Fund 1 LLLP | other | 96,154 |
| Jun 30, 17 | Bentovim Lyron L | other | 4,630 |
| Jun 30, 17 | Daniel Ran | other | 6,539 |
| Apr 18, 17 | Bentovim Lyron L | other | 1,960 |
| Feb 19, 17 | Bentovim Lyron L | other | 264,022 |
Our BLSP Coverage
We haven't published any research on BLSP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLSP Report →